CA-QUECTEL-WIRELESS
3.1.2023 10:01:41 CET | Business Wire | Press release
Quectel Wireless Solutions, a global IoT solutions provider, has announced the launch of the latest addition to its LTE module portfolio, the industrial grade EG800Q-EU LTE Cat.1 bis wireless communication module. An ultra-compact module in LGA form factor, the EG800Q-EU offers greater flexibility in IoT designs and enables a wider range of IoT use cases, particularly for size sensitive applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230103005121/en/
EG800Q-EU - ultra-compact, high-performance Cat.1 bis solution (Graphic: Business Wire)
Based upon the Qualcomm® QCX216 LTE IoT Modem from Qualcomm Technologies Inc., the EG800Q-EU is an LTE only module for customers in Europe, the Middle East, Africa, Australia, New Zealand, and Israel markets with LTE FDD band coverage of B1/ 3/ 5/ 7/ 8/ 20/ 28. The module delivers a maximum downlink data rate of 10 Mbps while enhancing battery life, critical for a variety of high-performing IoT applications including smart utility meters, asset trackers, e-mobility, parking meters, and home automation.
The EG800Q-EU’s support of Cat.1 bis allows it to use a single antenna, balancing cost and performance and making the module an ideal solution for IoT terminals that are designed to be compact and cost-effective.
“We feel very excited that our EG800Q-EU is one of the industry’s first Cat.1 modules based on the Qualcomm QCX216 LTE IoT Modem, a cost-optimized, power efficient global Cat.1 bis modem,” said Norbert Muhrer, President and CSO of Quectel. “The module’s unrivalled advantages make it ideal for a multitude of mid-range use cases and deployment scenarios which demand reliable and cost-effective communication solutions.”
The EG800Q-EU has a compact form factor of 15.8mm × 17.7mm × 2.4mm, enabling integrators and developers to design size sensitive applications easily. Its advanced LGA package enables fully automated manufacturing for high-volume applications.
The EG800Q-EU also provides a rich set of Internet protocols, and industry-standard interfaces including USB 2.0/ UART/ I2C/ PCM/ USIM, extending the suitability of the module to a variety of IoT applications such as asset management, remotely managed access control (RMAC), and smart grid. Additionally, the module supports DFOTA to enable automatic firmware upgrade and integrated Wi-Fi positioning services when there is no GPS signal indoors.
To help customers to facilitate their designs, Quectel offers a variety of high-performance LTE Cat.1 antennas which boost wireless connectivity significantly. IoT developers can bundle the EG800Q-EU module with Quectel’s antennas and pre-certification services, reducing both cost and time-to-market for their Cat.1 devices.
Engineering samples of the Quectel EG800Q-EU are available now.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
Qualcomm is a trademark or registered trademark of Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005121/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom